Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Aim(s): We explored the efficacy and tolerability of SSAs in sporadic non-functioning pNETs ≤2 cm.
Materials and methods: Patients with sporadic, NF, G1/G2 pNETs ≤2 cm were considered. Subjects with Multiple Endocrine Neoplasia or functioning-pNETs were excluded. Progression-free survival (PFS), response rate (RR) and toxicity were analyzed in subjects treated with SSAs (SSA group) and subjects which underwent active surveillance (AS group). Quality of life was registered using QLQ-C30 and QLQ-GI.NET21 questionnaires.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.